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Hybrid systems are constructs of different molecular
entities, natural or unnatural, to generate functional mole-
cules in which the characteristics of various components are
modulated, amplified or give rise to entirely new properties.
These hybrids can be designed from carefully selected
components either through domain integration of key
structural/ functional features or via straightforward cova-
lent linkages. Some of the recently reported hybrid systems
based on steroid, carbohydrate, C60-fullerene platforms,
amongst others, mainly crafted with the object of enhance-
ment of the therapeutical spectrum, will be discussed.
1 Introduction
One of the main goals of organic synthesis from its very
inception has been the search for new compounds that exhibit
novel physical, chemical and biological properties.1 In this
quest, human intuition and leads from Nature have played a
pivotal role. Nature makes natural products of bewildering
diversity and complexity and these are generally derived
through specific biosynthetic pathways like, shikimate, polyke-
tide or mevalonate, leading to a particular class of compounds.2
Many biologically active natural products are also derived
through mixed biosynthesis. This may involve either integration
of the different biosynthetic pathways to generate complex,
enmeshed structures or eventuate in straightforward covalent
linkage between components derived through different path-
ways. Examples of the former type are the complex indole
alkaloids, e.g. strychnine 1, which are derived from amino acid
tryptophan and monoterpenic precursor loganin and ansa
antibiotics like rifamycins 2 wherein the aromatic core is
shikimate derived while the ansa chain is polyketide based.2 On
the other hand, glycoproteins, chlorophyll 3, vitamin-B12 and
flavanoid and steroidal glycosides such as 4 (Fig. 1), to name a
few, are well known examples of natural products in which
various segments of the molecule have different biosynthetic
origin but are linked covalently into a wholesome functional
entity. Many of the natural products arising through such mixed
biosynthesis have been found to exhibit unusual properties and
biological activity as the different molecular segments act
cooperatively to control and modulate conformation, recogni-
tion, communication, transport and solubility among other
properties. These promising attributes of molecules of mixed
biosynthetic origin perhaps led to the idea of generating novel
molecular entities by rationally combining two or more
different classes of compounds of natural or synthetic origin.
The underlying expectation being that combination of structural
features of two or more functionally active substances into one
molecule or their covalent coupling may either enhance or
modulate the desired characteristics of individual components
or lead to new types of properties. An appealing feature of this
approach is that it may provide myriad possibilities for
generating a diverse array of new types of molecules for
application in biology and material science. During the past two
decades design of such entities has been receiving increasing
attention and these have been referred to in the literature as
‘hybrid molecules’ or ‘conjugates’ or ‘chimeras’ or even
‘mermaids’. Although, in strict terms ‘hybrid molecules’ refers
to structural motifs derived through domain integration of two
entities, in this review it has been used in an all inclusive sense
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and covers entities derived either through integration of
structural features or through covalent linkage of two or more
natural/unnatural products. Although the examples of hybrid
molecules are plenty, herein we wish to highlight some of the
recently crafted systems which have been devised to either
amplify certain characteristics, particularly the therapeutic
spectrum based on natural product leads, or to probe intricate
biochemical mechanisms. The selected examples discussed
here are based on the well-known building platforms like
steroids and C60-fullerene and involve incorporation of func-
tional entities like enediyne, nucleic acids, carbohydrates and
porphyrin moieties. Synthesis of such entities can either involve
intricate synthetic manipulations for structural integration or
simple, straightforward connectivity through functional groups.
Access to molecular hybrids through gene manipulations and
combinatorial biosynthesis is also under investigation but will
not be covered in this presentation.3 Organic–inorganic hybrid
systems which have been receiving a great deal of attention in
recent years as novel materials are also not discussed here.
2 Hybrids based on steroid framework
Steroids on account of their wide occurrence, particularly
among mammalian tissue, rigid framework with varying levels
of functionalisation, broad biological activity profile and ability
to penetrate the cell membrane and bind to specific hormonal
receptors have found favor as building platforms for hybrid
systems. Several molecular hybrids derived from diverse
steroids through integration and/or linkage with other bio-
molecules, drugs and other functional molecules have been
reported and a few notable examples will be discussed here. In
an effort to design a new class of cytotoxic agents, Tietze and
coworkers conceived of integrating the structural features of a
highly active mycotoxin (2)-talaromycin B 6 with the hormone
estrone 7 to devise a novel entity 5 (Fig. 2).4 Towards this end,
aldehyde 8 was obtained through the modification of ring D of
estrone. Reduction in 8 followed by iodoetherification and
elimination of HI furnished the tetracyclic derivative 9. Hetero
Diels–Alder reaction between 9 and 10 generated the required
spiroacetal 11 which was elaborated to the hybrid system 5
(Scheme 1). The cytotoxic activities of 5 and its precursor on
human cancer cells (cell line A 549) was determined and found
to be only slightly lower than that of aldophosphamide.
Fig. 1
Fig. 2
Scheme 1 Reagents and conditions: i, NaBH4, ii, I2, NaHCO3; iii, DBU; iv,
10; v, DIBAH; vi, PtO2, H2, 50 bar.
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Recognizing the importance of the anthraquinone subunit in
many biologically active natural products, and anticancer agents
like anthracyclines, De Riccardis and co-workers have crafted
steroid–anthraquinone hybrids 145 and estrogen–anthracene-
dione6 hybrids 18. While the CD rings of the steroid framework
are retained in the case of the former, the entire ABCD ring
framework is fused with the anthraquinone moiety in 18.
Synthesis of steroid–anthraquinone hybrid 14 is outlined in
Scheme 2 and involves a Diels–Alder reaction between vitamin
D3 derived dienes 13 and naphthoquinones 12 as the key step.
On evaluation of cytotoxic activity, these hybrids showed
promising results.5 The estrogen–anthracenedione hybrid 18
(estrarubicin) was also accessed through a Diels–Alder ap-
proach in which diene 15 derived from estrone was reacted with
the dienophile 16 to furnish 17. Subsequent transformations led
to estrarubicin 18 having structural integration of the steroid and
anthracycline-like moieties with an additional electrophilic
epoxide ring, Scheme 3.
Taking a clue from the observation that the benzoxazine
subunit is present in many natural products that exhibit
promising phytotoxicity, Schonecker and co-workers7 have
devised estrone–cyclic-hydroxamic acid hybrids 21 and 22
from nitroestrone 19 as shown in Scheme 4.
In view of the important role of baccatin III and related
taxoids in cancer chemotherapy, Danishefsky’s group8 con-
ceived and developed a route to baccatin III–cholesterol hybrid
27 in which the steroid A ring was elaborated to taxoid B ring.
Intramolecular Heck reaction in the precursor 26 leading to the
AB ring of taxane is the key element in this approach. The
intermediate 26 containing BCD rings of steroid was assembled
through the addition of the iododiene 23 to the aldehyde 24
derived from cholesterol, and subsequent manipulation of the
resulting intermediate 25, Scheme 5.
The exceptional promise of the enediyne moiety to effect
DNA cleavage through 1,4-diyl generated through Bergman
cycloaromatization and the discovery of several naturally
occurring cytotoxic agents like neocarzinostatin, the esper-
amycin–calicheamicin group and dynemicin bearing this moi-
ety inspired Wang and Clercq9 to design estramycin 32, a novel
steroid based hybrid. The expectation was that the chemother-
apeutic activity against hormone responsive tumors could be
enhanced through linkage with a steroid hormone. An enediyne
functionality was installed on the ring D of estrone through
addition of iododiyne 29 to the ketone 28 (readily available
from estrone) to give 30 which upon Nozaki coupling furnished
31 along with other diastereomers and was then converted into
the hybrid 32, Scheme 6.
Jones and co-workers10 have devised a new estramycin in
which the enediyne moiety is linked to the 17-position of the
hormone estradiol. Synthesis of the enediyne-estradiol hybrid
36 was achieved from estrone derivatives 33 and 34, Scheme 7.
Coupling with diyne alcohol 35 led to estramycin 36 a
promising lead compound which exhibited inhibition of
estrogen-induced transcription in T47-D human breast cancer
cells.
The ansa antibiotic geldanamycin (GDM) 37 (Fig. 3) is not
only a potent inhibitor of src kinase but also binds to the Hsp90
chaperone protein and causes the degradation of several
signaling proteins. In order to achieve selective degradation of
particular proteins for therapeutic applications, Danishefsky
Scheme 2 Reagents and conditions: i, heat; ii, DBU, O2.
Scheme 3 Reagents and conditions: i, LiClO4; ii, Zn, CH3COOH; iii,
Pb(OAc)4, CH3COOH; iv, Et3N; v, m-CPBA; vi, Pd/C, H2.
Scheme 4 Reagents and conditions: i, EtOCOCOCl, Et3N; ii, Pt(S)/C–H2,
AcOH; iii, BrCH2COOEt, K2CO3; iv, Zn, NH4Cl.
Scheme 5 Reagents and conditions: i, tBuLi; ii, tBu4NF; iii, [Pd(PPh3)4],
K2CO3; iv, PhLi; v, PDC, tBuOOH; vi, NaBH4, CeCl3.
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and co-workers have prepared hybrids 39 and 42 of geldanamy-
cin with estradiol and testosterone, respectively.11 Michael
addition of the amines 38a–d derived from estrone to GDM
gave the hybrids 39a–d with subtle variation in the tether,
Scheme 8. These hybrids were found to be active in MCF7
breast cancer cells and more selective than the parent causing
the degradation of ER and HER2 but not of other GDM targets.
Similarly, the male hormone testosterone 40 was elaborated into
amines 41 and linked to GDM to furnish hybrids 42, Scheme
9.12
A steroid–fullerene hybrid 44 has been prepared and its
cytotoxic effects at subcellular and cellular level examined.13
Union of C60-fullerene with steroid framework was effected
through a Diels–Alder cycloaddition with the diene 43 to
furnish the fullerene–steroid hybrid 44, Scheme 10. Preliminary
assay indicated that the hybrid 44 can inhibit the reconstituted
SR Ca2+-ATPase and affect the survival of A549 cells.
Regen and his associates14 designed novel constructs 47 and
48 (Fig. 4) which are endowed with features reminiscent of
amphotericin B 46, an antibiotic which is known to form pores
in lipid bilayers, and a marine natural product squalamine 45, a
sterol–spermidine conjugate. The effort was motivated by the
desire for antimicrobial activity against a broad spectrum of
microorganisms. Interestingly 48 exhibits antimicrobial proper-
ties similar to squalamine 45; the polyether 47 was found to be
inactive.
The potential of photo-dynamic therapy (PDT) as a promis-
ing non-invasive protocol against cancer has stimulated interest
in cholic acid–porphyrin, estrone–porphyrin and deoxycholic
acid–porphyrin–anthraquinone triads to combine a sensitizer
with a recognition element (bile acids, female sex hormones)
and an intercalating agent (anthraquinone). The derived hybrids
49, 5015 and 5116 (Fig. 5) exhibit nuclease activity.
3 Hybrids based on taxoids, anthracyclines and
b-lactams
As mentioned earlier, enhancement and fine-tuning the efficacy
of drugs was a major motivation for the design of hybrid
Scheme 6 Reagents and conditions: i, LiN(TMS)2; ii, TMSOTf; iii, CrCl2,
NiCl2.
Scheme 7 Reagents and conditions: i, TESCl, 94%; ii, nBuLi, CO2, 69%; iii,
1-ethyl-3-(3-dimethylaminopropyl)-carbodimide (EDCl), then TBAF,
78%.
Fig. 3
Scheme 8 Reagents and conditions: i, Geldanamycin, DMSO; ii, TBAF–
HOAc.
Scheme 9
Scheme 10 Reagents and conditions: i, C60, D; ii, p-TsOH, D.
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systems. Taxoids and anthracyclines represent two groups of
natural products, based on which several anti-cancer drugs are
in clinical use and it was a natural impulse of synthetic and
medicinal chemists to devise hybrids based on them.
Fallis and co-workers17 designed taxamycins 53 and 54
which contain ring A of taxol 52 and an enediyne moiety
connected through a bridge, Fig. 6. It was expected that both
tubulin binding and cycloaromatization would operate in
concordant manner and induce cancer cell damage. However,
these hybrid compounds were weaker than taxol in influencing
tubulin dynamics and their cytotoxic activity against HT-29
cancer cell lines was also weak.
Research groups of Kingston18 and Ojima19 have reported
several paclitaxel–macrocyclic constructs of which 55 and 56
(Fig. 7) are typical examples with the latter somewhat remotely
combining the structural features of taxoids with the well-
known cytotoxic agent epothilone. While these hybrids largely
retained the cytotoxicity of paclitaxel when evaluated against
human cancer cell lines, their tubulin binding ability was
diminished.
Fig. 4
Fig. 5
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In another approach to amplify the anti-cancer potency of
taxol 52, it has been linked with a porphyrin moiety through the
pharmacophorically benign C7 position to furnish hybrid 57
(Fig. 8). The idea was to complement the cytotoxic activity with
photodynamic action through light activation of the porphyrin,
a sort of dark and light therapy, to provide double lethal attack
against tumors.20
b-Lactam antibiotics have been in extensive use for over half
century but the persistent problem of drug resistance continues
to demand development of newer and potent variations. Banfi
and Guanti21 devised lactendiynes 61 in which a b-lactam ring
is fused to the 10-membered enediyne ring, Scheme 11. The b-
lactam 58 was transformed into 59 containing an enediyne
group. Oxidation and intramolecular Nozaki coupling led to
hybrid 60 along with its diastereoisomer. Several derivatives of
60 were prepared and one of them, the methyl ether 61 was
shown to undergo cycloaromatization indicating the inter-
vention of a 1,4-diyl species.
Danishefsky and co-workers have synthesized novel hybrids
by swapping the carbohydrate domain of two powerful anti-
cancer agents, the clinically used daunorubicin 62a and
calicheamicin g1 63 (Fig. 9). Thus, daunorubicinone 62b,
aglycon of 62a was glycosidated with the carbohydrate segment
of calicheamicins to furnish the hybrid species calichearubicins
65, Scheme 12.22 The objective 65, was reached through the
glycosidation of the protected trichloroacetamidate 64 in the
presence of AgOTf followed by deprotection to calichearubicin
A 65, Scheme 12. Similarly, calichearubicin B 66 was
synthesized via coupling of tethered daunorubicinone 62c and
64 followed by removal of protecting groups, Scheme 13.
Interaction of both 65 and 66 with DNA was studied and it was
observed that in the tethered hybrid 66, the anthracycline moiety
exhibits marked propensity towards intercalation. DNA foot
printing experiments with 65 and 66 led to the surmise that the
latter combines the unique specificities of its two compo-
nents.
4 Hybrids based on duocarmycin and CC-1065
Duocarmycin 67 and CC-1065 68 (Fig. 10) are a new class of
potent cytotoxic agents that alkylate DNA. In order to enhance
the therapeutic potential of these molecules efforts have been
made to combine their DNA alkylating structural part with a
moiety capable of sequence specific recognition. Consequently,
several groups have reported efforts in which the active
pharmocophoric segment of 67 and 68 has been linked to the
pyrrole or imidazole amide units present in lexitropsins, well
known for sequence specific recognition.
Groups of Shishido and Shibuya have developed hybrids
72a,b containing indoline unit, a precursor of the pharmaco-
phore moiety present in CC 1065 and duocarmycins, and
pyrrole amides, present in DNA minor groove binding lexitro-
psins, Scheme 14.23 It is interesting to note that hybrid 72a
having unnatural configuration was more potent than 72b with
natural configuration in DNA cleavage activity. The unnatural
hybrid 72a also exhibited DNA alkylation selectivity for the A-
T rich region.
In another approach Saito and co-workers24 synthesized
hybrids 76 that contain segments of duocarmycin A and pyrrole/
Fig. 6
Fig. 7
Fig. 8
Scheme 11 Reagents and conditions: i, Me3SiCCCHNCHCl, CuI,
[(PhCN)2PdCl2], piperidine; ii, AgNO3, NIS; iii, HF, H2O; iv, (COCl)2,
DMSO, Et3N; v, CrCl2, NiCl2.
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imidazole amide segments of distamycin.24 The pyrrole seg-
ment 74 was synthesized in several steps from 73 while the
duocarmycin segment 75 was readily obtained from duocarmy-
cin B2. Coupling of 74 with 75 furnished the desired hybrids 76,
Scheme 15. The results on DNA alkylation indicated that this is
a promising approach for alkylating purine bases at the desired
site.
Tietze et al. have conceptualized hybrids 77 and 78 of
indoline unit, a penultimate intermediate for the pharmacophore
moiety present in CC 1065, and carbohydrates. Thus, the
indoline derivative 80 was prepared from 79 via Heck reaction
and hydroboration. Reaction of 80 with tetracetyl-a-D-galacto-
syltrichloroacetimidate 81 and further manipulations gave the
pro-drug 77, Scheme 16. The b-D-glucoside 78 was also
synthesized along similar lines.25 The hybrids 77 and 78 were
evaluated for their toxicity against human bronchial carcinoma
cell line A 549.
5 Hybrids based on C60-fullerene
The discovery of C60 and its unusual physico-chemical
properties and reactivity has become a topic of interest in
medicinal chemistry and material science. Compounds derived
from C60 have shown promising biological profile and efficacy
in DNA photo-cleavage, HIV protease inhibition, neuroprotec-
tion and apoptosis. In order to harness these attributes and to
improve cellular level uptake, delivery and recognition, many
hybrids of C60 with molecules possessing biological affinity
like nucleic acids, proteins and carbohydrates have been
prepared. An early example is of the C60-netropsin related
hybrid 82 (Fig. 11) to achieve DNA cleavage specificity.26
Fig. 9
Scheme 12 Reagents and conditions: i, 62b, AgOTf, molecular sieves; ii, Ac2O, Py; iii, TBAF; iv, LiOH.
Scheme 13 Reagents and conditions: i, 62c, BF3·OEt2, molecular sieves; ii,
Ac2O, Py; iii, TBAF; iv, LiOH.
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Subsequently, several fullerene conjugates/hybrids for photo-
dynamic therapy (PDT) and sequence specific DNA cleavage
have been reported.27 Rubin and co-workers28 designed synthe-
sis of C60-linked deoxynucleotide (DHFDON-1) 83 (Fig. 12)
and it interacted with light and oxygen to damage only
guanosines in the single-stranded regions in DNA which are
closest to C60. Prato and co-workers29 designed synthesis of a
fullerene hybrid 84 (Fig. 12) containing a trimethoxyindole
(TMI) moiety reminiscent of the minor groove binder duo-
carmycin and a oligonuclotide for achieving sequence selectiv-
ity. Several groups have been actively engaged in the synthesis
of novel fullerene–porphyrin hybrids in which the fullerene and
porphyrin moieties are coupled through a variety of linkers
including a steroid 85 (Fig. 13).30 These fullerene porphyrin
hybrids were designed in the context of application in the PDT
of cancer.
Fig. 10
Scheme 14 Reagents and conditions: i, EDCl·HCl; ii, LiOH·H2O; iii, Ph3P,
CCl4; iv, BBr3.
Scheme 15 Reagents and conditions: i, 75, NaH, DMF, (X = N, 38%; X =
CH, 26%).
Scheme 16 Reagents and conditions: i, 81, BF3·OEt2, molecular sieves; ii,
TBAF, SiO2; iii, PPh3, CCl4; iv, K2CO3, MeOH.
Fig. 11
Fig. 12
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6 Carbohydrate–peptide hybrids
Glycoconjugates, particularly glycoproteins, play an important
role in various biological processes such as modulation of
protein function, cell growth and differentiation and cell–cell
communication. The oligosaccharide moiety present in the
glycoproteins and glycolipids, presumably has a key role in
their diverse biological functions. In view of this, there is a great
deal of interest in the design of carbohydrate–peptide hybrids as
glycopeptide mimics, and various strategies have been devised
for this purpose. While Wong’s group31 has employed Ugi’s
multi-component approach to generate a library of neomycin
mimetics 90 (Scheme 17), Nilsson et al.32 have adopted a
building block approach to prepare 1-thio-b-D-galactopyrano-
side–amino acid library 91 (Fig. 14) which was found to be a
good inhibitor of b-galactosidase from E. coli.
Carbohydrate–peptide derived oligomeric structures offer the
possibility of controlling shape and conformation and such
hybrid molecules may exhibit helical, hairpin and other
secondary structures. Two examples 92 and 93 (Fig. 15) of
carbopeptoid oligomeric structures from the groups of Fleet33
and Chakraborty,34 respectively, indicate emerging interest in
such designs.
Van Boom35 developed a parallel synthesis of cyclic sugar
amino acid–amino acid hybrids 97a, b as a new class of receptor
molecules endowed with structural elements of cyclodextrins
and cyclic peptides, Scheme 18.
Recently, hybrids based on a combination of macrolides and
nucleobases/nucleosides such as 98, 99 and their congeners
Fig. 13
Scheme 17
Scheme 18
Fig. 14
Fig. 15
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were synthesized by Costa and Vilarrasa (Fig. 16).36 However,
their biological activities were not promising.
7 Miscellaneous hybrids
Koert et al. have described the synthesis of hybrids 100 and 101
(Fig. 17) that contain structural features of annonaceous
acetogenins and ubiquinone with a view to design molecular
probes for studies on mitochondrial complex I (NADH–
ubiquinone oxidoreductase).37 It was observed that the qui-
none–mucocin 100 and the related quinone–squamocin D 101
hybrids were much more potent inhibitors of mitochondrial
complex I than mucocin.
Ugi and co-workers38 developed a synthetic route to
compounds of type 102 in which a b-lactam moiety is attached
to a nucleoside. The synthesis is based on multicomponent
reaction (MCR) approach in which a b-amino acid, oxo-
component and isocyanides react to form a b-lactam ring
(Scheme 19).
In the context of the design of new polycyclitols for selective
glycosidase inhibition, the synthesis of carbasugar hybrid 105
has been reported.39 Thus, the readily available precursor 103
was converted via extrusion of CO to diene 104 and this was
elaborated into the hybrid 105 through osmylation and depro-
tection of the acetonide moiety Scheme 20).
8 Conclusion
As we have seen, the possibilities of generating hybrid systems
for creating molecular diversity through either domain in-
tegration or covalent connection of two or more diverse entities
are almost unlimited. The possibility of assembling large,
nanoscopic, multi-component, multi-functional entities will
continue to engage the attention of organic chemists. Natural
products and leads emanating from them will be the bedrock of
these efforts. Even the tools of combinatorial chemistry can be
applied to yield libraries of hybrid molecules. However,
precision crafting is necessary to generate the desired character-
istics, particularly in the case of biologically active compounds
and natural products, where significant modulation and/or
enhancement of the therapeutic spectrum should be achievable.
A good many of the recently reported efforts on the creation of
hybrid systems have focused on cancer related chemother-
apeutic drugs. However, with the availability of the three
dimensional structures of many receptors and access to genome
sequences, creation of new hybrid systems for these new targets
is likely to receive increasing attention.
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